Fig. 3From: Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapyScatterplots of calprotectin (a, d), ESR (b, e), and CRP values (c, f) with corresponding clinical disease activity index (CDAI) values in tocilizumab (TCZ)-treated RA patients (a–c) and in tumor necrosis factor alpha-inhibitor (TNFi)-treated (d–f) RA patients. Significant correlations were detected between calprotectin and CDAI in TCZ- (a) and TNFi-treated patients (d), as well as between ESR (e) and CRP (f) with CDAI in TNFi-treated patientsBack to article page